Corporate
Profile

Failed to register as Favorite Page
Failed to cancel as Favorite Page
This page is already registered as a Favorite Page
You can't add your company to your favorites.

Latest update: 21/06/2022 15:26:16

Liid Pharmaceuticals, Inc.

Approaching Untreatable Disease Areas with Nucleic Acid Medicines

We will eliminate toxicity, a critical issue for nucleic acid medicines, with new concepts and bring out the potential of nucleic acid medicines.

Inquiry
Main image

Sales Pitch

BROTHERS Nucleic Acid
New Nucleic Acid Medicine Working by Kinetic Domination
The major sources of toxicity in nucleic acid medicines include "hybridization-independent" toxicity and "hybridization-dependent" toxicity. The former is primarily due to nonspecific protein adsorption, while the latter is mainly due to the degradation of non-target mRNA (off-target genes). In the conventional nucleic acid medicine field, safe nucleic acid medicines have been obtained through screening. However, our BROTHERS nucleic acid is a new concept of nucleic acid medicine that logically resolves the two toxic mechanisms simultaneously.
DDS-integrated Nucleic Acid Medicine
By utilizing our proprietary linker technology, organ-transferable molecules can be appropriately and efficiently modified into nucleic acid medicines. We are currently expanding the technology to increase the number of organs it can be applied to.

Catalogue/Pamphlet/Proposed

Liidサマリー.pdf

This company is recommended by the following support organizations.

Marketing Support Department, SMRJ

SDG Actions

GOOD HEALTH AND WELL-BEING
Inquiry